Rabies virus inactivated antigen, B

DB10062ApprovedInvestigationalVaccinesInactivated Rabies Virus Vaccine

Inactivated rabies virus antigen B is a component of rabies vaccines used for pre- and post-exposure prophylaxis against rabies.

Primary indication
Inactivated rabies virus antigen B is indicated for pre- and post-exposure prophylaxis against rabies.Curator reviewed · 1 structured indication
First approval
Canada, 2005 · United States, 1980
Also known as
Rabies virus strain PM-1503-3M antigen (propiolactone inactivated) · Rabies virus vaccine wistar strain PM-1503-3M (human)
Brand names
  • Imovax

Resolves to

Compound
UNIIC4HQF74XMW
Clinical / RWD
RxNorm830464ATCJ06AA06

What you can answer from here — as of April 02, 2025

291Drug interactionsStructured to mechanism, not free text
Sign in
24Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
10Marketed productsAcross 5 countries and 8 labellers
Sign in
1ATC codeIncluding every combination product, plus 7 drug categories
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which other approved drugs treat the same conditions as Rabies virus inactivated antigen, B, and which companies have late-stage candidates in those indications?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In